HealthQuill Novo Nordisk
Pfizer Inc., has discontinued its clinical trials of the twice-daily oral weight-loss drug, danuglipron, after more than 50% of the patients opted out due to adverse effects of the medicine.
Drugs Health Pharma

Pfizer Inc., stops twice-daily oral obesity drug trial at mid-stage

HQ Team December 2, 2023: Pfizer Inc., has discontinued its clinical trials of the twice-daily oral weight-loss drug, danuglipron, after more than 50%.

Read More
Eli Lilly’s weight-loss injection Zepbound, taken along as a supplement with diet and exercise, got the USFDA and UK regulator’s nod after clinical trials proved adults lost 48 pounds on average during treatment.
Drugs Medical Pharma

Eli Lilly’s Zepbound outperforms Novo’s Wegovy in weight loss study

HQ team November 28, 2023: A recent comparative analysis of Eli Lilly and Novo Nordisk’s weight loss drugs on diabetes patients showed Eli.

Read More
— at a time when President Emmanuel Macron is taking steps to stem the country’s industrial decline.
Drugs Health Pharma

Novo Nordisk invests $2.3b in France for diabetes, obesity drugs

HQ Team November 23, 2023: Novo Nordisk will invest $2.3 billion to expand production of its weight-loss and diabetes drug in Chartes, France..

Read More
Novo Nordisk plans to invest 42 million Danish kroner ($6 billion) in Denmark to create new capacities for making active pharmaceutical ingredients and expand its portfolio within serious chronic diseases.
Drugs Health Pharma

Novo Nordisk plans $6 billion investment to expand in Denmark

HQ Team November 10, 2023: Novo Nordisk plans to invest 42 million Danish kroner ($6 billion) in Denmark to create new capacities for.

Read More
Eli Lilly’s weight-loss injection Zepbound, taken along as a supplement with diet and exercise, got the USFDA and UK regulator’s nod after clinical trials proved adults lost 48 pounds on average during treatment.
Drugs Health Pharma

US, UK regulators give green light to Eli Lilly’s weight-loss treatment

HQ Team November 9, 2023: Eli Lilly’s weight-loss injection Zepbound, to be taken along as a supplement with diet and exercise, got the.

Read More
Drugs Health Pharma

Novo Nordisk to buy hypertension drug from KBP for $1.3 billion

HQ Team October 16, 2023: Danish pharmaceutical company, Novo Nordisk, announced it was buying a hypertension drug, still in trials, from Singapore-based KBP.

Read More
Dutch pharmaceutical company, Novo Nordisk, has stopped testing Ozempic to treat the progression of renal impairment in people with type 2 diabetes and chronic kidney disease after the interim results met certain pre-specified” criteria for efficacy.
Drugs Health Pharma

Novo Nordisk stops testing of Ozempic as kidney trial meets efficacy goals

HQ Team October 11, 2023: Dutch pharmaceutical company, Novo Nordisk, has stopped testing Ozempic to treat the progression of renal impairment in people.

Read More
Cardiometabolic diseases are a group of common but often preventable conditions including heart attack, stroke, diabetes, insulin resistance and non-alcoholic fatty liver disease.
Drugs Health Pharma

Novo Nordisk, Valo Health sign $2.7 billion pact for drug discovery

HQ Team September 25, 2023: Novo Nordisk and Valo Health, Inc., have signed a $2.7 billion pact to discover and develop novel treatments.

Read More
Semaglutide based weightloss drugs tied to increased suicide risk in a new study
Drugs Health Pharma

Novo Nordisk’s weight-loss drug Wegovy enters the UK market 

HQ Team September 4, 2023: Novo Nordisk, a Danish drugmaker, announced its weight-loss medicine, Wegovy, will be available in the UK in a.

Read More
Denmark’s Novo Nordisk will invest 15.9 billion kroner ($2.30 billion) to expand its Hillerød production facility in the country to make new active pharmaceutical ingredients.
Drugs Health Pharma

Novo Nordisk to invest $2.3 billion to expand Danish facility 

HQ Team June 13, 2023: Denmark’s Novo Nordisk will invest 15.9 billion kroner ($2.30 billion) to expand its Hillerød production facility in the.

Read More